Cargando...
Use of bevacizumab in recurrent glioblastoma
Glioblastoma (GBM) is the most common adult primary brain neoplasm. Despite advances in treatment, GBM continues to be associated with considerable morbidity and mortality as compared with other malignancies. Standard treatment for GBM results in survival of 12.9 months (95% CI: 12.3–13.7 months) wi...
Gardado en:
| Publicado en: | CNS Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Future Medicine Ltd
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088330/ https://ncbi.nlm.nih.gov/pubmed/25906439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.8 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|